1. Home
  2. TOVX vs GCTK Comparison

TOVX vs GCTK Comparison

Compare TOVX & GCTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TOVX
  • GCTK
  • Stock Information
  • Founded
  • TOVX 2001
  • GCTK 2001
  • Country
  • TOVX United States
  • GCTK United States
  • Employees
  • TOVX N/A
  • GCTK N/A
  • Industry
  • TOVX Biotechnology: Pharmaceutical Preparations
  • GCTK Medical/Dental Instruments
  • Sector
  • TOVX Health Care
  • GCTK Health Care
  • Exchange
  • TOVX Nasdaq
  • GCTK Nasdaq
  • Market Cap
  • TOVX 3.6M
  • GCTK N/A
  • IPO Year
  • TOVX 2006
  • GCTK N/A
  • Fundamental
  • Price
  • TOVX $0.64
  • GCTK $0.16
  • Analyst Decision
  • TOVX Hold
  • GCTK
  • Analyst Count
  • TOVX 1
  • GCTK 0
  • Target Price
  • TOVX N/A
  • GCTK N/A
  • AVG Volume (30 Days)
  • TOVX 2.4M
  • GCTK 6.4M
  • Earning Date
  • TOVX 05-20-2025
  • GCTK 05-20-2025
  • Dividend Yield
  • TOVX N/A
  • GCTK N/A
  • EPS Growth
  • TOVX N/A
  • GCTK N/A
  • EPS
  • TOVX N/A
  • GCTK N/A
  • Revenue
  • TOVX N/A
  • GCTK N/A
  • Revenue This Year
  • TOVX N/A
  • GCTK N/A
  • Revenue Next Year
  • TOVX N/A
  • GCTK N/A
  • P/E Ratio
  • TOVX N/A
  • GCTK N/A
  • Revenue Growth
  • TOVX N/A
  • GCTK N/A
  • 52 Week Low
  • TOVX $0.74
  • GCTK $0.13
  • 52 Week High
  • TOVX $12.25
  • GCTK $63.90
  • Technical
  • Relative Strength Index (RSI)
  • TOVX 23.36
  • GCTK 37.49
  • Support Level
  • TOVX $1.32
  • GCTK $0.15
  • Resistance Level
  • TOVX $1.45
  • GCTK $0.17
  • Average True Range (ATR)
  • TOVX 0.14
  • GCTK 0.02
  • MACD
  • TOVX -0.07
  • GCTK 0.01
  • Stochastic Oscillator
  • TOVX 2.92
  • GCTK 37.47

About TOVX Theriva Biologics Inc.

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Share on Social Networks: